Pharmaceuticals - Asia

Asia

In 2024, the projected revenue for the Pharmaceuticals market in Asia is expected to reach a staggering US$235.70bn.
The largest market within this industry is Oncology Drugs, with a projected market volume of US$44.87bn in 2024.
Looking ahead, the revenue is expected to display a steady annual growth rate (CAGR 2024-2028) of 6.69%, leading to a market volume of US$305.40bn by 2028.
When compared globally, it is worth noting that United States will generate the highest revenue, with an estimated US$636.90bn in 2024.
In Japan, the pharmaceutical market is driven by an aging population and increasing demand for innovative healthcare solutions.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Pharmaceuticals in Asia is on the rise due to various factors.

Customer preferences: As the population in Asia is aging, there is an increasing demand for pharmaceuticals to treat chronic diseases. Additionally, the rising middle class in Asia has led to an increase in disposable income, which has resulted in greater spending on healthcare and pharmaceutical products.

Trends in the market: In China, the pharmaceutical market is growing rapidly due to an aging population and increasing urbanization. The government's focus on healthcare reform has also led to an increase in demand for innovative drugs. In India, the market is growing due to the increasing prevalence of chronic diseases and a growing middle class. The government's push towards generic drugs has also led to increased demand. In Japan, the market is growing due to a rapidly aging population and an increase in healthcare spending.

Local special circumstances: In China, pharmaceutical companies face strict regulations and a complex approval process for new drugs. Additionally, the market is highly fragmented, with many small players competing for market share. In India, the market is highly price-sensitive, with consumers often opting for cheaper generic drugs over branded ones. In Japan, the market is dominated by a few large players, which makes it difficult for new entrants to gain a foothold.

Underlying macroeconomic factors: The overall economic growth in Asia has led to an increase in healthcare spending. Additionally, the aging population in many Asian countries has led to an increase in demand for pharmaceuticals. The rise of the middle class has also led to increased spending on healthcare and pharmaceuticals. However, the regulatory environment in many Asian countries can be challenging for pharmaceutical companies, which can limit growth opportunities.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.